Compare SAFE & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAFE | LBRX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1999 | N/A |
| Metric | SAFE | LBRX |
|---|---|---|
| Price | $16.19 | $45.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $19.00 | ★ $46.60 |
| AVG Volume (30 Days) | 274.0K | ★ 344.9K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.48% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $385,552,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $20.01 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $12.76 | $13.40 |
| 52 Week High | $17.45 | $46.01 |
| Indicator | SAFE | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 78.18 |
| Support Level | $13.99 | $27.40 |
| Resistance Level | $16.54 | N/A |
| Average True Range (ATR) | 0.49 | 2.95 |
| MACD | -0.07 | 1.08 |
| Stochastic Oscillator | 25.00 | 92.22 |
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.